Signal US federal drug agency funds non-hallucinogenic psychedelic development with $11.4 million

Summary

The Psychedelics and Healing Initiative reports that AtaiBeckley has received up to 11.4 million dollars in non-dilutive federal funding. The money comes from the National Institutes of Health through the National Institute on Drug Abuse. It supports the development of non-hallucinogenic 5-HT2A/2C agonists for treating opioid use disorder. Industry experts, the Initiative says, read the grant as a landmark endorsement of psychedelic-derived medicines that avoid hallucinations. The company states that the recognition strengthens its leadership in this drug space and speeds its timetable for reaching patients with addiction. GWI presents the award as federal validation of the neuroplastogen approach.